Nebulization as a delivery method for mAbs in respiratory diseases

Area of Science:

• Pulmonary drug delivery
• Biotherapeutics
• Respiratory medicine

Background:

• Pulmonary drug delivery offers targeted lung treatment, minimizing systemic side effects.
• It is an attractive alternative to intravenous administration for monoclonal antibodies (mAbs) due to limited blood-to-lung transfer.

Purpose of the Study:

• To review the pharmacological properties of antibody-based treatments for respiratory diseases.
• To discuss preclinical and clinical outcomes of inhaled antibody therapeutics.
• To detail aerosol device considerations and formulation strategies for mAb administration.

Main Methods:

• Review of existing literature on aerosolized antibody therapeutics.
• Analysis of pharmacological properties and delivery devices for mAbs.
• Evaluation of preclinical and clinical data for inhaled antibody treatments.

Main Results:

• Inhalation of mAbs for therapeutic lung targeting is feasible and appropriate.
• Molecular properties like size and structure are crucial for sustained lung retention.
• Mesh nebulizers show promise for delivering substantial amounts of active mAbs.

Conclusions:

• Optimizing mAb formulation is essential to prevent degradation and immunogenicity.
• Tailoring device and formulation combinations to specific therapeutic needs is critical.
• Aerosolized mAbs represent a viable therapeutic strategy for lung diseases.